---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280116"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:20:21.572072+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay

## Summary
- Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
- Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.
- Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay.

## SEC filing metadata
- accession: 0001193125-25-280116
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/0001193125-25-280116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/cvsi-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280116
- JSON: https://secwatch.observer/filing/0001193125-25-280116.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.